BOSTON, Mass--Researchers at New England Deaconess Hospital are seeking Hodgkin's disease patients for a federally funded phase Ib/II trial of a humanized monoclonal antibody (MoAb) against interleukin-2 receptor (Tac).
BOSTON, Mass--Researchers at New England Deaconess Hospital areseeking Hodgkin's disease patients for a federally funded phaseIb/II trial of a humanized monoclonal antibody (MoAb) againstinterleukin-2 receptor (Tac).
The rationale for the study stems from the observation that allReed-Sternberg cells are Tac-positive. The monoclonal antibodyunder study is the humanized version of the murine anti-Tac antibodythat generated a 33% response rate (partial response plus completeresponse) in 19 patients with ATL (adult T-cell leukemia/lymphoma)at the National Cancer Institute (see figure).
The new molecule is 92% human in origin, resulting in increasedeffectiveness in cytotoxicity assays and reduced immunogenicityduring therapy (Queen et al: Proc Natl Acad Sci USA 86:10029,1989; Junghans et al: Cancer Research 50:1495, 1990).
Eligibility requirements for the protocol (92-0205-34) includemeasurable disease, failed first- and second-line treatments,and PS 0-2. Patients must be able to remain in Boston for thefirst study month of this outpatient trial. Treatment responseat 1 month is required to continue participation.
For more information, contact Richard P. Junghans, PhD, MD, atNew England Deaconess Hospital; telephone:
617-632-0943; fax: 617-632-0998.
Expanding Horizons in T-Cell Lymphoma Therapy: Focus on Personalized Treatment Strategies
Several lymphoma experts discuss the current T-cell lymphoma landscape, the need for new therapies, and ongoing research in the space.
Highlighting Insights From the Marginal Zone Lymphoma Workshop
Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.